Empowering cancer vaccine development from ‘Tumour to Target’
In the evolving landscape of cancer research, where immunology-based therapies hold immense promise, Platinum Discovery is emerging as a pivotal partner, driving innovation in the field of anti-cancer vaccines. As a Scottish pre-clinical research company, Platinum Discovery specialises in immunopeptidomics, proteomics, and related protein chemistry and analytics. With a unique combination of scientific expertise and innovative technology, Platinum Discovery offers an end-to-end drug discovery platform designed to accelerate the evaluation and development of life-saving cancer vaccines.
Expertise rooted in science
Platinum Discovery stands out in the cancer research ecosystem due to its profound understanding of the human proteome and the technological prowess required to analyse it. The core capability lies in the identification and characterisation of cancer neoantigens—unique, tumour-specific antigens that are the essential building blocks for the design and development of targeted cancer vaccines and related immunotherapies. The company leverages advanced mass spectrometry, integrated multiomics approaches, and sophisticated data analytics to delve deep into clinical samples, unlocking cellular insights that were previously out of reach.
Platinum Discovery’s services rely on its interdisciplinary team of scientists, clinicians, and bioinformaticians. This multidisciplinary approach allows the company to break down traditional barriers between biological, clinical, and computational sciences, fostering innovation in cancer vaccine development.
A technological powerhouse
One of Platinum Discovery’s key strengths is its access to one of Europe’s largest and most well-equipped mass spectrometry facilities. This access ensures that the company can offer advanced processes and analyses, allowing it to stay at the forefront of technological advancements in cancer research. By combining mass spectrometry with immunopeptidomics—a branch of proteomics focused on studying peptides presented by Major Histocompatibility Complexes (MHC) on the surface of cancer cells—Platinum Discovery can directly identify tumour-specific antigens with unprecedented accuracy.
Collaborations that drive innovation
Platinum Discovery’s extensive network of clinical partners provides ethical access to a wide variety of patient samples, spanning multiple tumour types. This access is crucial for discovering tumour-specific antigens that can be used to develop vaccines tailored to the unique characteristics of each cancer type. By working with small biopsy-size tissue from patient samples, Platinum Discovery can support translational work with phase 1 clinical patients, enabling earlier and more targeted interventions. The company’s strong relationships with clinical institutions ensure that they can operate with freedom for commercial applications, making them a valuable partner in the rapidly growing field of immunotherapy.
Platinum Discovery’s impact on cancer research is further amplified by its strategic partnerships with leading academic centres, researchers, and clinical scientists. These collaborations enable the company to stay at the forefront of research, gaining access to emerging technologies and novel insights that propel their work forward. Through these partnerships, Platinum Discovery offers its collaborators not only technical expertise but also a deep understanding of the scientific processes underpinning successful drug development.
Innovating for cancers of unmet need
At the core of Platinum Discovery’s mission is a commitment to addressing cancers of unmet need. Many forms of cancer, particularly those that are rare or aggressive, today lack effective treatment options. Platinum Discovery’s Tumour to Target platform is specifically designed to target these cancers, using neoantigen discovery and characterisation to develop vaccines that offer new hope to patients who have exhausted traditional therapies.
Their work is driven by the belief that every cancer patient deserves a personalised treatment plan, tailored to the specific genetic and molecular characteristics of their disease. By focusing on tumour-specific antigens and leveraging their innovative technological platform, Platinum Discovery is accelerating the delivery of cancer vaccines that have the potential to transform outcomes for patients worldwide.
Shaping the next era of cancer vaccines
Platinum Discovery is a research organisation that combines deep scientific expertise with advanced technology to drive innovation in cancer vaccine development. From tumour to target, the company provides end-to-end solutions that support the discovery of life-saving therapies for cancers with unmet medical needs. With a solid foundation in immunopeptidomics, proteomics, and mass spectrometry, and a collaborative approach that leverages partnerships with academic and clinical experts, Platinum Discovery is poised to make a lasting impact on the future of cancer treatment.
